<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438776</url>
  </required_header>
  <id_info>
    <org_study_id>F1D-US-X165</org_study_id>
    <nct_id>NCT00438776</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lindner Center of HOPE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lindner Center of HOPE</source>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the efficacy (effectiveness) and safety of&#xD;
      olanzapine in treating pathological gambling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS)</measure>
    <time_frame>per protocol</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Pathological Gambling</condition>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active zyprexa (olanzapine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (fake pill)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>2.5mg to 15mg daily</description>
    <arm_group_label>olanzapine</arm_group_label>
    <other_name>zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>matching placebo to olanzapine</description>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>fake pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female outpatients aged 18- 75 years of age.&#xD;
&#xD;
          2. Patients will have problematic gambling behavior of at least 6 months duration that&#xD;
             meets the DSM-IV definition of pathological gambling and a South Oaks Gambling Screen&#xD;
             Score greater than 5.&#xD;
&#xD;
          3. All patients will have a complete medical and psychiatric history, physical&#xD;
             examination, laboratories, and ECG before study entry.&#xD;
&#xD;
          4. Baseline laboratory values and ECG must be normal, or abnormalities must be clinically&#xD;
             insignificant.&#xD;
&#xD;
          5. Patients will not have received any psychotropic medication for at least one week&#xD;
             prior to the first study visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have any significant and/or unstable gastrointestinal, neurological,&#xD;
             endocrine, cardiovascular, pulmonary, renal, hepatic, immunological or hematological&#xD;
             disease; organic brain disease; or cancer as determined by history, physical, ECG, and&#xD;
             laboratory examination.&#xD;
&#xD;
          2. Patients who are pregnant, intending to become pregnant, nursing, at risk for&#xD;
             pregnancy, or not practicing medically acceptable birth control. (A blood pregnancy&#xD;
             test will be performed at the screening visit).&#xD;
&#xD;
          3. Patients who have ever had psychotic symptoms, who have ever met DSM-IV criteria for a&#xD;
             manic episode (i.e., have bipolar I disorder), or who have met criteria for DSM-IV&#xD;
             psychoactive substance dependence in the past 1 month.&#xD;
&#xD;
          4. Patients who meet DSM-IV criteria for antisocial or borderline personality disorder.&#xD;
&#xD;
          5. Patients who use any medications which, in the judgment of the investigator, might&#xD;
             have psychotropic effects, or interact unfavorably with olanzapine. For example,&#xD;
             patients taking diet pills or stimulants will not be enrolled.&#xD;
&#xD;
          6. Patients who have taken any psychiatric medication within 7 days prior to the&#xD;
             screening assessment.&#xD;
&#xD;
          7. Patients who have a history of hypersensitivity to olanzapine.&#xD;
&#xD;
          8. Patients who display clinically significant suicidal ideation.&#xD;
&#xD;
          9. Patients who have recently (within the past 3 months) begun any type of&#xD;
             non-pharmacologic treatment for pathological gambling (including psychotherapy,&#xD;
             behavior therapy, group therapy, or family therapy). This does not exclude&#xD;
             participation in support groups (e.g., Gamblers Anonymous.) Patients who have been&#xD;
             involved in long-standing psychological therapies (e.g., psychotherapy for at least&#xD;
             the last 3 months) will be permitted to continue in that therapy provided that no new&#xD;
             therapeutic technique or increase in frequency of psychotherapy occurs concurrent with&#xD;
             the study.&#xD;
&#xD;
         10. Patients who exhibit or suggest that they may display behavior that will not be&#xD;
             conducive to the study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan L McElroy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008 Mar;69(3):433-40.</citation>
    <PMID>18251624</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gambling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

